Epigenetic EZH2 dependency in KRAS inhibitor-resistant PDAC cells (AACRPanCa 2026) - Oct 15, 2026 - Abstract #B061; "Combined treatment of Tazemetostat and MRTX1133 re-sensitized resistant cells, leading to a significant reduction in cell viability alongside cell death induction. Remarkably, Tazemetostat synergized with the dual mTOR/PI3K inhibitor Dactolisib to significantly reduce cell viability, providing an alternative therapeutic option...In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026; 86(18_Suppl_2):Abstract nr B061."
Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • ASCL1 • CDH1 • CDH2 • CHGA • CLDN1 • KRAS • PAX6 • SNAI2
|
|
Gonçalo Outeiro-Pinho; Aref Hosseini; Maciej Garczyk; Stephan von. Gunten; Beat Gloor; Anna Silvia. Wenning; Hannah L. Williams; Martin Wartenberg; Georgia Konstantinidou
|